Loading stock data…
LFCR
$4.50-0.29 (-6.05%)
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lifecore Biomedical, Inc. in the Healthcare sector is trading at $4.50. The stock is currently near its 52-week low of $3.63, remaining 34.8% below its 200-day moving average. Technical signals show neutral RSI of 30 and bearish MACD signal, explaining why LFCR maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.50
Potential Upside
5%
Whystock Fair Value$4.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$196.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
367.44%
Volume
Today's trading volume
242,486
Recent News
Lifecore Biomedical Q1 Earnings Call Highlights
Lifecore Biomedical (NASDAQ:LFCR) executives highlighted new commercial site transfer wins, continued cost reductions, and improving liquidity during the company’s first-quarter 2026 earnings call, while acknowledging a year-over-year revenue decline tied to previously discussed headwinds. Manageme
Laughing Water Capital’s Insights on Lifecore Biomedical (LFCR)
Laughing Water Capital, an investment management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Class A investment in Laughing Water Capital returned approximately -4.5% net of all fees and expenses in the first quarter of 2026. The SP500TR and R2000 returned -4.3% and 0.9% respectively, during the […]
When Should You Buy Lifecore Biomedical, Inc. (NASDAQ:LFCR)?
Lifecore Biomedical, Inc. ( NASDAQ:LFCR ), is not the largest company out there, but it saw significant share price...
Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029
Lifecore Biomedical (NASDAQ:LFCR) CEO Paul Josephs told investors at a KeyBanc conference that the company has completed its transition into a “standalone CDMO” after divesting its former food businesses in 2022 and 2023. Josephs said Lifecore is now focused on two primary operations at its single s
Lifecore Biomedical Inc (LFCR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Lifecore Biomedical Inc (LFCR) reports a 10% revenue increase in Q4 2025 and outlines strategic initiatives to drive future growth despite anticipated challenges.